Literature DB >> 32961552

Mutational landscape of gray zone lymphoma.

Clémentine Sarkozy1,2, Stacy S Hung1, Elizabeth A Chavez1, Gerben Duns1, Katsuyoshi Takata1, Lauren C Chong1, Tomohiro Aoki1, Aixiang Jiang1, Tomoko Miyata-Takata1, Adèle Telenius1, Graham W Slack1, Thierry Jo Molina3, Susana Ben-Neriah1, Pedro Farinha1, Peggy Dartigues4, Diane Damotte5,6, Anja Mottok7, Gilles A Salles2,8, Rene-Olivier Casasnovas9, Kerry J Savage1, Camille Laurent10, David W Scott1, Alexandra Traverse-Glehen2,11, Christian Steidl1.   

Abstract

The mutational landscape of gray zone lymphoma (GZL) has not yet been established, and differences from related entities are largely unknown. Here, we studied coding sequence mutations of 50 Epstein-Barr virus (EBV)-negative GZLs and 20 polymorphic EBV+ diffuse large B-cell lymphoma (DLBCL) not otherwise specified (poly-EBV-L) in comparison with classical Hodgkin lymphoma (cHL), primary mediastinal large B-cell lymphoma (PMBCL), and DLBCL. Exomes of 21 GZL and 7 poly-EBV-L cases, along with paired constitutional DNA, were analyzed as a discovery cohort, followed by targeted sequencing of 217 genes in an extension cohort of 29 GZL and 13 poly-EBV-L cases. GZL cases with thymic niche involvement (anterior mediastinal mass) exhibited a mutation profile closely resembling cHL and PMBCL, with SOCS1 (45%), B2M (45%), TNFAIP3 (35%), GNA13 (35%), LRRN3 (32%), and NFKBIA (29%) being the most recurrently mutated genes. In contrast, GZL cases without thymic niche involvement (n = 18) had a significantly distinct pattern that was enriched in mutations related to apoptosis defects (TP53 [39%], BCL2 [28%], BIRC6 [22%]) and depleted in GNA13, XPO1, or NF-κB signaling pathway mutations (TNFAIP3, NFKBIE, IKBKB, NFKBIA). They also exhibited more BCL2/BCL6 rearrangements compared with thymic GZL. Poly-EBV-L cases presented a distinct mutational profile, including STAT3 mutations and a significantly lower coding mutation load in comparison with EBV- GZL. Our study highlights characteristic mutational patterns in GZL associated with presentation in the thymic niche, suggesting a common cell of origin and disease evolution overlapping with related anterior mediastinal lymphomas.
© 2021 by The American Society of Hematology.

Entities:  

Year:  2021        PMID: 32961552     DOI: 10.1182/blood.2020007507

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Taking gray zone lymphomas out of the shadows.

Authors:  Elías Campo; Elaine S Jaffe
Journal:  Blood       Date:  2021-04-01       Impact factor: 22.113

Review 2.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Authors:  Rita Alaggio; Catalina Amador; Ioannis Anagnostopoulos; Ayoma D Attygalle; Iguaracyra Barreto de Oliveira Araujo; Emilio Berti; Govind Bhagat; Anita Maria Borges; Daniel Boyer; Mariarita Calaminici; Amy Chadburn; John K C Chan; Wah Cheuk; Wee-Joo Chng; John K Choi; Shih-Sung Chuang; Sarah E Coupland; Magdalena Czader; Sandeep S Dave; Daphne de Jong; Ming-Qing Du; Kojo S Elenitoba-Johnson; Judith Ferry; Julia Geyer; Dita Gratzinger; Joan Guitart; Sumeet Gujral; Marian Harris; Christine J Harrison; Sylvia Hartmann; Andreas Hochhaus; Patty M Jansen; Kennosuke Karube; Werner Kempf; Joseph Khoury; Hiroshi Kimura; Wolfram Klapper; Alexandra E Kovach; Shaji Kumar; Alexander J Lazar; Stefano Lazzi; Lorenzo Leoncini; Nelson Leung; Vasiliki Leventaki; Xiao-Qiu Li; Megan S Lim; Wei-Ping Liu; Abner Louissaint; Andrea Marcogliese; L Jeffrey Medeiros; Michael Michal; Roberto N Miranda; Christina Mitteldorf; Santiago Montes-Moreno; William Morice; Valentina Nardi; Kikkeri N Naresh; Yasodha Natkunam; Siok-Bian Ng; Ilske Oschlies; German Ott; Marie Parrens; Melissa Pulitzer; S Vincent Rajkumar; Andrew C Rawstron; Karen Rech; Andreas Rosenwald; Jonathan Said; Clémentine Sarkozy; Shahin Sayed; Caner Saygin; Anna Schuh; William Sewell; Reiner Siebert; Aliyah R Sohani; Reuben Tooze; Alexandra Traverse-Glehen; Francisco Vega; Beatrice Vergier; Ashutosh D Wechalekar; Brent Wood; Luc Xerri; Wenbin Xiao
Journal:  Leukemia       Date:  2022-06-22       Impact factor: 12.883

Review 3.  Evolution in the definition and diagnosis of the Hodgkin lymphomas and related entities.

Authors:  Thomas A Tousseyn; Rebecca L King; Falko Fend; Andrew L Feldman; Pierre Brousset; Elaine S Jaffe
Journal:  Virchows Arch       Date:  2022-10-24       Impact factor: 4.535

4.  Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.

Authors:  Niklas Gebauer; Axel Künstner; Julius Ketzer; Hanno M Witte; Tobias Rausch; Vladimir Benes; Jürgen Zimmermann; Judith Gebauer; Hartmut Merz; Veronica Bernard; Lana Harder; Katharina Ratjen; Stefan Gesk; Wolfgang Peter; Yannik Busch; Peter Trojok; Nikolas von Bubnoff; Harald Biersack; Hauke Busch; Alfred C Feller
Journal:  Blood Cancer J       Date:  2021-05-26       Impact factor: 11.037

5.  Concurrent Composite Lymphomas Collectively Bearing Three Diagnostic Entities of Shared Clonal Origin.

Authors:  Waleed Alduaij; Laura K Hilton; Muntadhar Al Moosawi; Susana Ben-Neriah; Barbara Meissner; Merrill Boyle; Kelly Mekwunye; David W Scott; Heather A Leitch; Jeffrey W Craig
Journal:  Hemasphere       Date:  2022-03-29

Review 6.  The Grey Zones of Classic Hodgkin Lymphoma.

Authors:  Jan Bosch-Schips; Massimo Granai; Leticia Quintanilla-Martinez; Falko Fend
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

7.  Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France.

Authors:  Marie Donzel; Maxime Bonjour; Jean-Damien Combes; Florence Broussais; Pierre Sesques; Alexandra Traverse-Glehen; Catherine de Martel
Journal:  EClinicalMedicine       Date:  2022-10-01

Review 8.  Application of precision medicine in clinical routine in haematology-Challenges and opportunities.

Authors:  Tove Wästerlid; Lucia Cavelier; Claudia Haferlach; Marina Konopleva; Stefan Fröhling; Päivi Östling; Lars Bullinger; Thoas Fioretos; Karin E Smedby
Journal:  J Intern Med       Date:  2022-06-04       Impact factor: 13.068

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.